{"id":566,"date":"2015-01-27T11:00:08","date_gmt":"2015-01-27T11:00:08","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=566"},"modified":"2017-08-21T12:01:47","modified_gmt":"2017-08-21T12:01:47","slug":"primary-care-corner-with-geoffrey-modest-md-mrsa-treatment","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/01\/27\/primary-care-corner-with-geoffrey-modest-md-mrsa-treatment\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: MRSA treatment"},"content":{"rendered":"<p><b>By: Dr. Geoffrey Modest<\/b><\/p>\n<p>As we are well aware here , methicillin-resistant staph (MRSA) infections are very common in the community. We have had very good success overall with trimethoprim\/sulfa (TMP\/SMX), though for deep-seated infections, I have prescribed linezolid (which is very expense, &gt;$100\/pill, and requires a prior approval). So, being strongly prior-approval averse, I was impressed with a Swedish trial showing non-inferiority between TMP\/SMX plus rifampin and linezolid (see <strong>doi:10.1093\/jac\/dku352<\/strong>). Study publically-funded.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"http:\/\/upload.wikimedia.org\/wikipedia\/commons\/6\/64\/MRSA_SEM_9994_lores.jpg\" alt=\"\" width=\"300\" height=\"300\" \/>Details:<\/p>\n<p style=\"padding-left: 30px\">&#8211;150 patients (ave age 69, 68% male, 93% hospitalized for infection but of those 31% were elective admission), most with significant comorbidities (63% cardiovasc,17% pulm, 20% renal, 25% cancer\u2026) given either TMP\/SMX DS tid plus rifampin 600 daily vs. linezolid 600 bid<br \/>\n&#8211;All had had sensitivity testing and found to be susceptible to all of the meds prior to randomization<br \/>\n&#8211;Most had deep-seated infections, though 30% had \u201cskin and soft tissue infection\u201d<br \/>\n&#8211;Median duration of therapy 12 days<br \/>\n&#8211;On intention-to-treat analysis, no difference (75% in linezolid and 79% with TPM\/SMX plus rifampin were cured on assessment at 6 weeks). For per-protocol analysis, also no difference (82% in linezolid and 88% with TPM\/SMX plus rifampin were cured on assessment at 6 weeks). No difference by type\/severity of infection, mortality.<br \/>\n&#8211;Adverse reactions were common in both groups (66%), with serious adverse events in 15 pts. with linezolid and 16 on combo regimen; also nonsignificant difference in adverse reactions directly attributable to linezolid (4) and combo (9)<\/p>\n<p>So, potentially useful study. The vast majority of patients with MRSA seen as outpatients here respond well to TMP\/SMX alone, and I would not change that. Though, before doing that in other areas, it would be useful to know community-based sensitivities of MRSA, since we do not know the patient\u2019s bacterial sensitivities prior to starting therapy, and would only use TMP\/SMX if low level of community resistance (I would guess reasonable cutoff would be around 15%, esp. if the infection is not so severe). However, for patients who have more severe skin infections (and I have gone through the painful prior-approval process a couple of times for linezolid), it seems reasonable to me to try TMP\/SMX plus rifampin (watching for drug-drug interactions, esp. with rifampin) and follow the patient closely.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MRSA treatment [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/01\/27\/primary-care-corner-with-geoffrey-modest-md-mrsa-treatment\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-566","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=566"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/566\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}